Cardiac amyloidosis is increasingly recognized as an underdiagnosed cause of heart failure, arrhythmias, and unexplained left ventricular hypertrophy. The Amyloid Imaging session explores how noninvasive imaging modalities are reshaping detection, subtyping, and monitoring of amyloid cardiomyopathy. Participants will examine the role of bone-avid scintigraphy tracers, cardiac MRI, and PET imaging in differentiating transthyretin (ATTR) from light-chain (AL) amyloidosis, guiding biopsy decisions, and tracking treatment response over time. By focusing on practical image interpretation and real-world workflows, this session supports cardiologists, imagers, and heart failure specialists who want to integrate amyloid protocols into their daily practice.

With more clinicians searching for an Cardiology conference to gain confidence in diagnosis, there is a growing need to standardize reporting, acquisition protocols, and multidisciplinary decision-making. This session reviews key imaging patterns, semi-quantitative scoring systems, and pitfalls that can lead to misclassification. Attendees will learn how to combine imaging findings with clinical features, biomarkers, and genetic testing to confirm ATTR or AL amyloidosis and avoid unnecessary procedures. Case-based discussions will highlight scenarios such as low-voltage ECG with thick walls, aortic stenosis with suspected amyloid, and coexisting hypertrophic cardiomyopathy, emphasizing when to suspect amyloid and how to escalate investigations appropriately.

A major emphasis is placed on cardiac amyloidosis imaging as a tool for prognosis and treatment planning. The session will show how imaging can stratify disease severity, inform decisions about tafamidis, chemotherapy, or clinical trial enrollment, and support longitudinal assessment of therapy response. Participants will learn practical tips for setting up amyloid imaging workflows, coordinating with nuclear medicine and radiology departments, and building interdisciplinary amyloid clinics. Attention is also given to communicating results clearly with referring clinicians and patients, ensuring that complex imaging language translates into meaningful, actionable care plans.

The session concludes by exploring emerging tracers, quantitative imaging techniques, and the integration of artificial intelligence to enhance pattern recognition and early detection. By the end, participants will be better equipped to recognize when amyloidosis should be on the differential diagnosis, order the right test at the right time, and interpret results confidently in the context of the overall clinical picture.